Market Cap 145.69M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,357,700
Avg Vol 1,752,412
Day's Range N/A - N/A
Shares Out 66.53M
Stochastic %K 92%
Beta 1.62
Analysts Strong Sell
Price Target $10.50

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.19 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
User123321
User123321 Oct. 5 at 12:22 AM
$CRDF Thanks for reposting frogman’s post. I’m sure he and T also known as Todd from Yahoo appreciate it. 😀 My take is the data and any partnership will do the talking. Hopefully it’s enough to overcome the buffoonery in the C-Suite.
0 · Reply
DCRMIA
DCRMIA Oct. 4 at 9:32 PM
$CRDF 📈🚀👀
0 · Reply
BullRun4
BullRun4 Oct. 4 at 2:02 PM
$CRDF https://www.linkedin.com/posts/linkedhealth-innovations_oncology-biotech-investorevent-activity-7379658855032696832-vGP6?utm_medium=ios_app&rcm=ACoAAAPZvKEBMr9oVTfqP2LL2Wm-6no5eI4XoJU&utm_source=screenshot_social_share&utm_campaign=copy_link
0 · Reply
BullRun4
BullRun4 Oct. 4 at 1:23 AM
$CRDF Onvansertib targets PLK1, a key mitotic kinase and metabolic reprogramming hub in RAS-mutant tumors. This supports broad applicability (G12D, G12V, NRAS, etc.) vs. niche KRAS G12C inhibitors (Lumakras, Krazati). With scans q8 weeks and enrollment complete, PFS and DoR curves should mature meaningfully by Dec 2025–Feb 2026. High CR rate in KRAS-mutant is unprecedented vs SOC. Median DoR ≥ 12 mo would be a significant differentiator vs. SoC (~5–6 mo typical), and CR count reaching 10–12 would strongly reinforce biological effect. There’s real scientific heft behind PLK1 inhibition as a therapeutic strategy — not only cell-cycle arrest but metabolic reprogramming that plausibly explains deepening and durable clinical responses. The preclinical and translational package is stronger than most Phase-2-era programs and the randomized Phase-2 clinical signal (CRs in the drug arm vs none in control) already materially de-risks the biology.
1 · Reply
DCRMIA
DCRMIA Oct. 3 at 2:49 PM
$CRDF one day, sooner than later, CRDF will skyrocket . Hype up!🚀📈🇺🇸
0 · Reply
Gypsygirl2
Gypsygirl2 Oct. 3 at 2:38 PM
$CRDF If you’re here for a quick flip? Keep on going’ but one day news will hit and this will imo open up above $70 or higher. Too many things on the burner with this co that you can’t ignore. All have peace in your heart!
1 · Reply
look2theblue
look2theblue Oct. 3 at 1:57 PM
$CRDF Best for this to creep up slowly as people unfamiliar figure out what's coming. Makes for better FOMO later. Hopefully this caps out around 2-3% at most into the weekend close.
0 · Reply
mark31
mark31 Oct. 3 at 1:42 PM
$CRDF early here no rush
1 · Reply
BullRun4
BullRun4 Oct. 3 at 1:15 PM
$CRDF buy it on sale for $2.12, it should be valued at $7 today. This is a bargain at $2
1 · Reply
Latest News on CRDF
Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 2 months ago

Cardiff Oncology: Data Update Resolves Some Signals


Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 3 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief


Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 5 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy


Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 7 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript


Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 7 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences


Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript


LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CRDF Current Share Price: $2.19 Contracts: $CRDF January 15, 2027 $5 Calls Scale in: $1.35- $1.65 Scale out: $2.10-$2.70 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
User123321
User123321 Oct. 5 at 12:22 AM
$CRDF Thanks for reposting frogman’s post. I’m sure he and T also known as Todd from Yahoo appreciate it. 😀 My take is the data and any partnership will do the talking. Hopefully it’s enough to overcome the buffoonery in the C-Suite.
0 · Reply
DCRMIA
DCRMIA Oct. 4 at 9:32 PM
$CRDF 📈🚀👀
0 · Reply
BullRun4
BullRun4 Oct. 4 at 2:02 PM
$CRDF https://www.linkedin.com/posts/linkedhealth-innovations_oncology-biotech-investorevent-activity-7379658855032696832-vGP6?utm_medium=ios_app&rcm=ACoAAAPZvKEBMr9oVTfqP2LL2Wm-6no5eI4XoJU&utm_source=screenshot_social_share&utm_campaign=copy_link
0 · Reply
BullRun4
BullRun4 Oct. 4 at 1:23 AM
$CRDF Onvansertib targets PLK1, a key mitotic kinase and metabolic reprogramming hub in RAS-mutant tumors. This supports broad applicability (G12D, G12V, NRAS, etc.) vs. niche KRAS G12C inhibitors (Lumakras, Krazati). With scans q8 weeks and enrollment complete, PFS and DoR curves should mature meaningfully by Dec 2025–Feb 2026. High CR rate in KRAS-mutant is unprecedented vs SOC. Median DoR ≥ 12 mo would be a significant differentiator vs. SoC (~5–6 mo typical), and CR count reaching 10–12 would strongly reinforce biological effect. There’s real scientific heft behind PLK1 inhibition as a therapeutic strategy — not only cell-cycle arrest but metabolic reprogramming that plausibly explains deepening and durable clinical responses. The preclinical and translational package is stronger than most Phase-2-era programs and the randomized Phase-2 clinical signal (CRs in the drug arm vs none in control) already materially de-risks the biology.
1 · Reply
DCRMIA
DCRMIA Oct. 3 at 2:49 PM
$CRDF one day, sooner than later, CRDF will skyrocket . Hype up!🚀📈🇺🇸
0 · Reply
Gypsygirl2
Gypsygirl2 Oct. 3 at 2:38 PM
$CRDF If you’re here for a quick flip? Keep on going’ but one day news will hit and this will imo open up above $70 or higher. Too many things on the burner with this co that you can’t ignore. All have peace in your heart!
1 · Reply
look2theblue
look2theblue Oct. 3 at 1:57 PM
$CRDF Best for this to creep up slowly as people unfamiliar figure out what's coming. Makes for better FOMO later. Hopefully this caps out around 2-3% at most into the weekend close.
0 · Reply
mark31
mark31 Oct. 3 at 1:42 PM
$CRDF early here no rush
1 · Reply
BullRun4
BullRun4 Oct. 3 at 1:15 PM
$CRDF buy it on sale for $2.12, it should be valued at $7 today. This is a bargain at $2
1 · Reply
McGinvests
McGinvests Oct. 3 at 4:31 AM
$CRDF Who is ready to hear Erlander take a lot of time to say nothing
2 · Reply
Cutlass
Cutlass Oct. 2 at 9:33 PM
$CRDF Well let's see where this goes the next few months - cautiously optimistic that they are starting the road shows off in early October 📋⏳🔎
1 · Reply
mark31
mark31 Oct. 2 at 8:26 PM
1 · Reply
Cutlass
Cutlass Oct. 2 at 8:06 PM
$CRDF Two-Fer = SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.(CRDF) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO) Date: 10/09/2025 Time: 1:00 PM ET Contact Piper Sandler for information on attending the conference. Noble Capital Markets’ Emerging Growth Virtual Equity Conference Format: Fireside Chat Presenter: Mark Erlander, CEO Date: 10/09/2025 Time: 2:00 PM ET
0 · Reply
Channelchek
Channelchek Oct. 2 at 4:43 PM
We're excited to feature Cardiff Oncology ($CRDF) as a participating company at the Noble Capital Markets Emerging Growth Virtual Equity Conference, October 8-9. Don't miss the chance to explore unique investment opportunities. 1x1 Meetings available for qualified investors. 📅 Register: https://www.meetmax.com/sched/event_125441/investor_reg_new.html?attendee_role_id=NOBLE_INVESTOR #NobleConference #EmergingGrowth #InvestorEvent #CardiffOncology
0 · Reply
BillionDollarDreams
BillionDollarDreams Oct. 2 at 12:56 PM
$SPY $BULL $APLD $CRDF Let's go!! 😁 Green af today!
0 · Reply
PSDL75
PSDL75 Oct. 2 at 10:19 AM
0 · Reply
Oknrv
Oknrv Oct. 2 at 1:47 AM
$CRDF Price flat. On balance Volume creeping up.
0 · Reply
look2theblue
look2theblue Oct. 1 at 11:45 PM
$CRDF the bat signal is sneaking through... A move higher is coming.
0 · Reply
BullRun4
BullRun4 Oct. 1 at 10:26 PM
$CRDF very quiet lately! Not much said!!
2 · Reply
mark31
mark31 Oct. 1 at 2:46 PM
$CRDF nice volume
1 · Reply
mark31
mark31 Oct. 1 at 2:08 PM
$CRDF no rush
0 · Reply